Horizon Therapeutics
Amgen to cut 350 jobs after acquiring Horizon for $28 billion
Recently, in the aftermath of Amgen’s substantial $27.8 billion acquisition of Horizon, unveiled in December and finalized this month, these ...
Amgen Successfully Completes $27.8B Acquisition of Horizon After FTC Dispute Resolution
Amgen has successfully concluded its monumental $27.8 billion acquisition of Horizon Therapeutics, triumphing over a legal challenge posed by the ...
Amgen seals the deal with Horizon for $28 billion, expanding its portfolio of rare disease drugs
After several months of legal battles, Amgen has finally received the green light for its $27.8 billion acquisition of Horizon ...
FTC’s Legal Pas de Deux: A Pause in the Amgen-Horizon Acquisition
In the world of corporate clashes and strategic maneuvers, a legal ballet is unfolding, with the Federal Trade Commission (FTC) ...
Amgen challenges FTC’s bid to block $28B Horizon deal
Amid the ongoing legal battle with the Federal Trade Commission (FTC) over its $28 billion acquisition of Horizon Therapeutics, Amgen ...
Horizon Surpasses Roche in Rare Disease Reputation, While Pfizer’s Standing Declines
Horizon Therapeutics continues to collect accolades as it progresses toward its acquisition, with rare disease organizations now recognizing its excellence. ...
Long-Term Results from MIRROR Trial: KRYSTEXXA Injection Combined with Methotrexate Reveals Promising Outcomes
Source – Horizon On July 6, 2023, Horizon Therapeutics announced the publication of long-term data from the MIRROR randomized controlled ...
Positive new Phase III MRI results from the NMOSD study UPLIZNA
Source – Horizon Therapeutics Horizon Therapeutics unveiled positive MRI data from a Phase III clinical trial of UPLIZNA (inebilizumab) at ...
